12:30 PM
 | 
Dec 17, 2018
 |  BioCentury  |  Finance

Versant’s base case

Why Versant is bumping up cash per company with its latest funds

Versant Ventures plans to allocate more funding per start-up out of its newest funds, reflecting the firm’s shift towards building stand-alone companies with large portfolios.

On Monday, Versant closed Versant Venture Capital VII at $600 million and Versant Voyageurs I, its Canadian companion fund, at $100 million.

Fund VII will invest in more than 20 therapeutics companies in the U.S., Canada and Europe, with more than half headed to spinouts from Versant’s incubators and the remainder to traditional investments.

“Our base case is to ensure our companies are well-capitalized enough not to need partnerships,” said...

Read the full 453 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >